A NOVEL ANTIBIOTIC TO TREAT BACTERIAL CONJUNCTIVITIS – BESIFLOXACIN

Clicks: 1
ID: 309284
2023
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #153 of 153 articles by views in International Journal of Pharmaceutical Drug Design (IJPDD)

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 153 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The prevalence of bacterial conjunctivitis, popularly known as pink eye, which is caused by a variety of aerobic and anaerobic bacteria, is unaffected by demographics. To avoid possibly irreversible eye damage, prompt empiric therapy with a wide-ranging anti-infective, including a surface fluoroquinolone, is essential. The growth in methicillin-resistant Staphylococcus samples to ocular illness as well as fluoroquinolone resistance patterns throughout persons with various ocular bacterial infections need the development of novel eye-specific medicines. Besifloxacin, a brand-new broad-spectrum fluoroquinolone medication, has been approved for the treatment of bacterial conjunctivitis. It is associated with a decreased rate of resistance development and inhibits DNA gyrase and topoisomerase IV with a distinctly balanced dual-targeting activity. The only bacterial populations that are exposed to besifloxacin are those in and around the eye because it is not available in other formulations. By deliberately avoiding direct besifloxacin interaction with bacteria because a consequence of widespread use, this lowers the risk that bacterial tolerance might develop.In vitro, besifloxacin shown equal or greater activity than other common topical antibiotics. In clinical trials, besifloxacin has frequently demonstrated efficacy and safety in treating individuals with bacterial conjunctivitis. Besifloxacin is considered safe, well tolerated, and has no known side effects.
Reference Key
imported_1761930196_6904ebd4046c8 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Priyanka Ramisetty
Journal International Journal of Pharmaceutical Drug Design (IJPDD)
Year 2023
DOI
10.62896/269mps08
URL
https://ijpdd.org/index.php/files/article/view/76
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.